Ugur Sahin, CEO and Co-Founder of BioNTech: "We at BioNTech are closely following the tragic situation in Ukraine and our thoughts are with everyone affected. As a company with employees from 60 countries, we know that diversity and community are stronger than pursuing single-sided interests. We join the call of the global community and urge those involved to return to peaceful coexistence in the region for the sake of all people.
"We are supporting humanitarian aid in Ukraine with a donation of one million Euro to the nonprofit organization for refugee relief 'UNO-Flüchtlingshilfe' - the partner of UN Refugee Agency (UNHCR) in Germany. Furthermore, we inform our employees about mental health support and examine further measures to alleviate the humanitarian catastrophe. On behalf of the entire Executive Management Board, I would like to thank our employees who donated already on their own. In these difficult times, this is also a special sign to our colleagues with Ukrainian roots."
About BioNTech
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma and Pfizer.